Last updated 3 days ago

AMAZE 12: A Research Study Investigating How Well the Medicine NNC0487-0111 Helps People With Excess Body Weight Maintain Their Weight Loss

600 patients around the world

Available in Argentina, United States

Novo Nordisk A/S

4Research sites

600Patients around the world

This study is for people with

Obesity

From 18 Years

All Gender

: Male or female (sex at birth).
Age 18 years or above at the time of signing the informed consent.

: Glycated haemoglobin (HbA1c) greater than or equal to ≥ 6.5% [48 millimoles per mole (mmol/mol)] as measured by the central laboratory at screening.
History of type 1 or type 2 diabetes mellitus as declared by the participant or reported in the medical records.
Treatment with glucagon-like-peptide-1 (GLP-1) receptor agonists (RA), dual GLP 1/gastric inhibitory peptide (GIP) RAs (or any other GLP-1 based treatment), or amylin analogues before screening.

CIPREC Centro de Investigación y Prevención Cardiovascular - CABA

Arenales 1611 2 piso, C1061 Cdad. Autónoma de Buenos Aires, Argentina

Instituto de Investigaciones Clínicas Mar del Plata

Av. Colón 3456, Mar del Plata, Buenos Aires

CONEXA Investigación Clínica S.A.

Pasaje Rivarola 111, Piso 3º, Oficina 9, CABA

Cicemo

Eduardo Acevedo 42, C1405BUB Cdad. Autónoma de Buenos Aires, Argentina

StudyAMAZE 12

SponsorNovo Nordisk A/S

Study typeInterventional

Conditions

Obesity

Requirements

From 18 YearsAll Gender

Unique study IDclinicaltrials.gov

NCT07503210